针对基质:针对持续性心房动的基于机制的废除策略
Gabriela-Elena Marascu1,2, Alexandru Ioan Deaconu1,2, Raluca-Elena Mitran2
1Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania.
Journal of clinical medicine
|July 29, 2025
概括
肺静脉隔离 (PVI) 是心房动 (AF) 的关键. 对于持久性AF,使用先进技术和AI的个性化基质策略显示出更好的结果.
科学领域:
- 电子生理学 电子生理学
- 心血管医学 心血管医学
- 医疗技术 医疗技术 医学技术
背景情况:
- 肺静脉隔离 (PVI) 是对心房动 (AF) 的首要治疗方法,特别是心房动.
- 持久性肌肉缺陷 (PsAF) 涉及复杂的机制,其中单独的PVI可能不足.
- 基于基质的废弃策略在PsAF管理中越来越重要.
研究的目的:
- 审查当前和新兴的心房移除策略.
- 突出个性化,基底式方法在持久性AF中的作用.
- 讨论废弃技术和绘图技术的进步.
主要方法:
- 关于PVI和AF消去的当前文献的综述.
- 讨论不同的废弃方式:射频,冷废弃和脉冲场废弃.
- 探索先进的映射技术和人工智能/机器学习在ablation.
主要成果:
- PVI对阳性AF有效,但PSAF需要更复杂的策略.
- 基于基质的个性化除显著改善了PsAF的结果.
- 像脉冲场切除和人工智能这样的新兴技术为更安全,更精确的治疗提供了潜力.
结论:
- 虽然PVI是基础性的,但针对性基质切除对于持续性AF至关重要.
- 包括人工智能在内的除技术和映射方面的进步正在为个性化AF管理铺平道路.
- 未来的研究应该专注于优化这些先进的战略,以实现长期的疗效.
相关概念视频
Dysrhythmias VI: Management of Dysrhythmias
107
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
107
Disturbances in Heart Rhythm
1.3K
Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
1.3K
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
168
Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...
168
Cardiopulmonary Resuscitation IV: Pharmacological Management
78
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
78
Mechanism of Cardiac Arrhythmias
1.1K
Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
1.1K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
859
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
859


